← Today’s ReceiptsOfficial public filing linked
Public-record receiptD-RIOfficial filing linked
Sheldon Whitehouse disclosed SELL $JNJ
Here’s the public record: who traded, what they disclosed, when it happened, how late it appeared, and what context is attached.
Trade range
$15K – $50K
Filed
2024-08-21
Trade date
2024-07-03
Disclosure lag
49 days after trade
Why this receipt matters
A quick read before you share it.
These are factual context points from the receipt and linked public-record data. They explain why the disclosure may be worth opening, not whether anyone acted improperly.
1The receipt links to an official public filing, so readers can verify the underlying disclosure before sharing.
2The filing appeared 49 days after the trade date, beyond the standard 45-day STOCK Act window.
3The disclosed range is $15K – $50K, which is the public reporting band rather than an exact profit or loss figure.
410 nearby same-ticker disclosures appeared in the surrounding 30-day window.
5Committee context is available for Sheldon Whitehouse, but PoliWealth treats it as context - not proof of intent or wrongdoing.
Source
Official filing ↗
Source: official House/Senate financial disclosure record · filing ID 659af64a-f12f-43f9-b4f4-0a7bcf3d3613 · filed 2024-08-21 · disclosed 49d after transaction
Market context
Johnson & Johnson
Sector: Healthcare
Factual flags
- Filed after the standard 45-day STOCK Act window.
- 10 nearby same-ticker disclosures in the surrounding 30-day window.
- Sits on committee with jurisdiction over healthcare/pharma sector — traded JNJ on 2024-07-03
- 9 trades filed on 2024-08-21 (batch dump)
- Filed 49 days after transaction (STOCK Act limit: 45)
Member trail
Sheldon Whitehouse
U.S. Senate · RI
Senate Committee on Environment and Public WorksSenate Committee on FinanceSenate Committee on the BudgetSenate Committee on the JudiciaryUnited States Senate Caucus on International Narcotics ControlCommission on Security and Cooperation in Europe
Ticker trail
$JNJ
Johnson & Johnson
Follow this tickerAlert me when this ticker gets a new congressional receipt. This page reports public disclosures and factual context only. It does not determine intent, is not an accusation, and is not investment advice.